Skip to content

Author

H. V. van Santen

We have 3 of 248 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

P256 - ECE_2728 - Impact of setmelanotide on metabolic index scores in Phase 3 trial participants with acquired hypothalamic obesity

The findings highlight the broad metabolic benefits and strong clinically meaningful efficacy of setmelanotide in this population, supporting its potential as a therapeutic option for patients with aHO and suggest reductions in visceral fat burden, hepatic steatosis, and overall cardiometabolic risk.

H. V. van Santen, S. Phillips, J. Hamilton et al. · 0 citations
Open access Aug 2026

P255 - ECE_1844 - Efficacy and safety of setmelanotide in acquired hypothalamic obesity: Results from a double-blind, multicentre, placebo-controlled, randomised phase 3 trial

Hypothalamic melanocortin-4 receptor (MC4R) signalling is crucial for regulating hunger, satiety, and energy expenditure. Tumour/treatment-induced or traumatic brain injury to the hypothalamus can lead to hyperphagia and acquired hypothalamic obesity (aHO), for which no approved treatments exist. We present resul...

Susan A. Phillips, H. V. van Santen, J. Hamilton et al. · 0 citations
Clinical trial Open access Jul 2026

Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.

Setmelanotide led to significantly greater reductions in BMI and hunger than placebo at 52 weeks among participants 4 to 66 years of age with acquired hypothalamic obesity.

J. Miller, H. V. van Santen, Susan A. Phillips et al. · 6 citations · ⚡2

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.